XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Commitment to Issue Class A Common Stock and Stockholders’ Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Notes payable
Class A Common Stock
Class A Common Stock
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Class A Common Stock
Common Stock
Class A Common Stock
Notes payable
Common Stock
Class B Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Notes payable
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2021       0                  
Beginning balance at Dec. 31, 2021       $ 0                  
Beginning balance (Accounting Standards Update 2020-06) at Dec. 31, 2021         $ 32,900                
Ending balance (in shares) at Mar. 31, 2022       0                  
Ending balance at Mar. 31, 2022       $ 32,900                  
Beginning balance (in shares) at Dec. 31, 2021           168,693,323   0          
Beginning balance at Dec. 31, 2021 $ 567,654         $ 17   $ 0 $ 3,482,226   $ (6,945) $ (2,907,644)  
Beginning balance (Accounting Standards Update 2020-06) at Dec. 31, 2021   $ (20,265)                     $ (20,265)
Beginning balance (Accounting Standards Update 2016-02) at Dec. 31, 2021   3,393                     3,393
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Reclassification of earnout shares liability to equity as part of authorized share increase                 5,014        
Issuance of shares (in shares)           68,742,020   64,000,588          
Issuance of shares 0         $ 7   $ 6 (13)        
Stock-based compensation (as restated) 3,347               3,347        
Exercise of stock options (in shares)           761,675              
Exercise of stock options 1,855               1,855        
Foreign Currency translation adjustment (564)                   (564)    
Net loss (153,098)                     (153,098)  
Ending balance (in shares) at Mar. 31, 2022           238,197,018   64,000,588          
Ending balance at Mar. 31, 2022 402,322         $ 24   $ 6 3,487,415   (7,509) (3,077,614)  
Beginning balance (in shares) at Dec. 31, 2021       0                  
Beginning balance at Dec. 31, 2021       $ 0                  
Beginning balance (Accounting Standards Update 2020-06) at Dec. 31, 2021         $ 32,900                
Beginning balance (in shares) at Dec. 31, 2021           168,693,323   0          
Beginning balance at Dec. 31, 2021 567,654         $ 17   $ 0 3,482,226   (6,945) (2,907,644)  
Beginning balance (Accounting Standards Update 2020-06) at Dec. 31, 2021   (20,265)                     (20,265)
Beginning balance (Accounting Standards Update 2016-02) at Dec. 31, 2021   $ 3,393                     $ 3,393
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Reclassification of liability for insufficient authorized shares related to stock options and RSUs (as restated) $ (4,000)                        
Ending balance (in shares) at Dec. 31, 2022 627,346,804         563,346,216   64,000,588          
Ending balance at Dec. 31, 2022 $ 200,992         $ 56   $ 6 3,724,180   3,505 (3,526,755)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Conversion of notes payable and accrued interest into Class A Common Stock (Note 10) (as restated) (in shares)             223,539,619            
Conversion of notes payable and accrued interest into Class A Common Stock (Note 10) (as restated)     $ 138,180       $ 22     $ 138,158      
Change in classification of warrants from Additional paid-in capital to liability pursuant to the Warrant Exchange (Note 10) (6,811)               (6,811)        
Reclassification of earnout shares liability to equity as part of authorized share increase 5,014               5,000        
Reclassification of liability for insufficient authorized shares related to stock options and RSUs (as restated) 8,978               8,978        
Stock-based compensation (as restated) 3,631               3,631        
Exercise of warrants (in shares)           51,128,708              
Exercise of warrants (as restated) 51,276         $ 5     51,271        
Exercise of stock options (in shares)           49,456              
Exercise of stock options 44               44        
Issuance of shares for RSU vesting (in shares)           808,040              
Issuance of shares for RSU vesting 1         $ 1              
Foreign Currency translation adjustment (555)                   (555)    
Net loss $ (144,973)                     (144,973)  
Ending balance (in shares) at Mar. 31, 2023 902,872,627         838,872,039   64,000,588          
Ending balance at Mar. 31, 2023 $ 255,777         $ 84   $ 6 $ 3,924,465   $ 2,950 $ (3,671,728)